Earum Pharmaceuticals Ltd Stock Analysis

BSE: 542724 | NSE: | Trading | Small Cap

BSE Share Price 07-Feb-2023 18:01
2.39 -0.02 (-0.83%)

DeciZen - Make an Informed Decision on Earum Pharmaceutical

M-Cap below 100cr DeciZen not available

Earum Pharmaceutical Price Chart

P/E Ratio ( SA) :
Market Cap :
14.9 Cr.
52-wk low :
52-wk high :
Bole Toh?

1. Is Earum Pharmaceuticals Ltd a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Earum Pharmaceuticals Ltd is a below average quality company.

2. Is Earum Pharmaceuticals Ltd undervalued or overvalued?

The key valuation ratios of Earum Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

3. Is Earum Pharmaceuticals Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Earum Pharmaceuticals Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Earum Pharmaceutical:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Earum Pharmaceuticals Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

ROCE % 11.6%14.7%17.9%17.4%12.7%3%8.9%-
Value Creation Index -

Growth Parameters

Growth Parameters Colour Code Guide

Sales 18.623.335.450.755.141.12121
YoY Gr. Rt. %-25.7%51.8%43.1%8.7%-25.5%-48.8%-
YoY Gr. Rt. %-40%119.6%85.3%-94.5%-96.7%3500%-
BVPS (₹) 12.714.
Adj Net Profit
Cash Flow from Ops. -0.30.1-7.1-0.5-3.5-7.12.6-
Debt/CF from Ops. -7.224.1-1-20-2.7-1.63.4-


CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales NA-2.1%-25.4%-48.8%
Adj EPS NA-23%-59.5%3500%
BVPS 0-28.2-4815.3
Share Price - - -18.4% -70.5%

Key Financial Parameters

Performance Ratio Colour Code Guide

Return on Equity % 7.49.92830.817.90.614.33.6
Op. Profit Mgn %
Net Profit Mgn %
Debt to Equity
Working Cap Days 0149155151182264479364
Cash Conv. Cycle 0718996112205443210

Recent Performance Summary

Debt to equity has declined versus last 3 years average to 0.52

Sales growth is good in last 4 quarters at 14.04%

Return on Equity has declined versus last 3 years average to 3.60%

Sales growth has been subdued in last 3 years 0.00%

Net Profit has been subdued in last 3 years -59.48%

Latest Financials - Earum Pharmaceuticals Ltd.

Standalone Consolidated
TTM EPS (₹) 0.1 -
TTM Sales (₹ Cr.) 21 -
BVPS (₹.) 2.8 -
Reserves (₹ Cr.) 5 -
P/BV 0.87 -
PE 23.34 -
From the Market
52 Week Low / High (₹) 2.20 / 8.38
All Time Low / High (₹) 2.20 / 26.40
Market Cap (₹ Cr.) 14.9
Equity (₹ Cr.) 12.3
Face Value (₹) 2
Industry PE 47.7

Management X-Ray of Earum Pharmaceutical :

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Earum Pharmaceutical

Adj EPS (Rs.)
Sales (Cr.)
ROE (%)
ROCE (%)


Earum Pharmaceuticals Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Earum Pharmaceutical on 07-Feb-2023 18:01 is : 2.39.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 07-Feb-2023 18:01 the market cap of Earum Pharmaceutical stood at ₹ 14.86.
The latest PE ratio of Earum Pharmaceutical as of 07-Feb-2023 18:01 is 23.34.
The latest PB ratio of Earum Pharmaceutical as of 07-Feb-2023 18:01 is 0.87
The 52-week high of Earum Pharmaceutical is ₹ 8.38 and the 52-week low is ₹ 2.20.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue / sales of Earum Pharmaceutical is ₹ 21.02 ( Cr.) .

About Earum Pharmaceuticals Ltd

Earum Pharmaceuticals

Earum Pharmaceuticals was originally incorporated as 'Earum Pharmaceuticals Private Limited' on July 26, 2012 vide Registration no. 071299 under the provisions of the Companies Act, 1956 with the Registrar of Companies, Gujarat, Dadra and Nagar Havelli. Further, pursuant to Special Resolution passed by the shareholders at the Extra Ordinary General Meeting held on January 10, 2019, the company was converted into a Public Limited Company and consequently the name of the Company was changed from 'Earum Pharmaceuticals Private Limited' to 'Earum Pharmaceuticals Limited' vide a fresh Certificate of Incorporation dated January 23, 2019 issued by the Registrar of Companies, Ahmedabad. The Corporate Identification Number of the Company post conversion.

Business area of the company

The company is engaged in the pharmaceutical business involving marketing, trading and distribution of wide range of pharmaceutical formulation products such as anti-biotic drugs, anti-malarial drugs, anti-allergic & anti cold drugs, analgesic/ anti-pyretic & anti inflammatory drugs, dermatology products, cerebral activator drugs, neurological drugs, gastro intestinal drugs, steroids, gynecology drugs, calcium, multivitamins, anti-oxidants and injections.  Apart from pharmaceutical formulation products, it also deals in trading of active pharmaceutical ingredients (API’s) such as Levofloxacin Hemihdrate IP, Albendazol IP, Amoxicillin Trihydrate IP etc.

2012: Incorporation of the Company in the name of 'Earum Pharmaceuticals Private Limited'.
2014-15: Total turnover of the Company reached to Rs. 8 crores.
2015-16: Crossed Turnover of Rs. 18 crores.
2016-17: Crossed Turnover of Rs. 23 crores.
2017-18: Crossed Turnover of Rs. 35 crores.
2019: Conversion of the Company from Private Limited to Public Limited Company.

Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now